Novel Strategies to Enhance Vaccine Immunity against Coccidioidomycosis

PLoS Pathogens

Volumn 9, Issue 12, 2013, Pages 1-4

  Cole, Garry T ^a   Hung, Chiung Yu ^a   Sanderson, Sam D ^b   Hurtgen, Brady J ^c   Wüthrich, Marcel ^d   Klein, Bruce S ^d   Deepe, George S ^e   Ostroff, Gary R ^f   Levitz, Stuart M ^f  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LIVE VACCINE; TUMOR NECROSIS FACTOR ALPHA; FUNGUS VACCINE;

ARTICLE; CELLULAR IMMUNITY; COCCIDIOIDES IMMITIS; COCCIDIOIDES POSADASII; COCCIDIOIDOMYCOSIS; DISEASE TRANSMISSION; GENETIC HETEROGENEITY; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INNATE IMMUNITY; PATHOGENESIS; T LYMPHOCYTE ACTIVATION; VACCINATION; ACTIVE IMMUNIZATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; COCCIDIOIDES; DRUG DELIVERY SYSTEM; IMMUNOLOGY; METHODOLOGY; MOUSE; STANDARD; TREATMENT OUTCOME;

ANIMALS; COCCIDIOIDES; COCCIDIOIDOMYCOSIS; DRUG DELIVERY SYSTEMS; FUNGAL VACCINES; HUMANS; IMMUNITY, ACTIVE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TREATMENT OUTCOME; VACCINATION; VACCINES, LIVE, UNATTENUATED;

EID: 84892901005     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003768     Document Type: Article

References (26)

1. Fisher FS, Bultman MW, Johnson SM, Pappagianis D, Zaborsky E, (2007) Coccidioides niches and habitat parameters in the southwestern United States: a matter of scale. Ann N Y Acad Sci 1111: 47-72.
2. Blundell GP, Castleberry MW, Lowe EP, Converse JL, (1961) The pathology of Coccidioides immitis in the Macaca mulatta. Am J Pathol 39: 613-630.
3. Wise HZ, Hung CY, Whiston E, Taylor JW, Cole GT, (2013) Extracellular ammonia at sites of pulmonary infection with Coccidioides posadasii contributes to severity of the respiratory disease. Microb Pathog 59-60: 19-28.
4. Anonymous (2013) Increase in reported coccidioidomycosis- United States, 1998-2011. Morb Mortal Wkly Rep 62: 217-221.
5. Marsden-Haug N, Goldoft M, Ralston C, Limaye AP, Chua J, et al. (2013) Coccidioidomycosis acquired in Washington State. Clin Infect Dis 56: 847-850.
6. Ruddy BE, Mayer AP, KO MG, Labonte HR, Borovansky JA, et al. (2011) Coccidioidomycosis in African Americans. Mayo Clin Proc 86: 63-69.
7. Cole GT, Hurtgen BJ, Hung C-Y, (2012) Progress toward a human vaccine against coccidioidomycosis. Curr Fungal Infect Rep 6: 235-244.
8. Pappagianis D, (1993) Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Study Group. Am Rev Respir Dis 148: 656-660.
9. Xue J, Chen X, Selby D, Hung-Y, Yu J-J, Cole GT, (2009) A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun 77: 3196-3208.
10. Balamayooran T, Batra S, Balamayooran G, Cai S, Kobayashi KS, et al. (2011) Receptor-interacting protein 2 controls pulmonary host defense to Escherichia coli infection via the regulation of interleukin-17A. Infect Immun 79: 4588-4599.
11. Hung C-Y, Gonzalez A, Wüthrich M, Klein BS, Cole GT, (2011) Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17). Infect Immun 79: 4511-4522.
12. Hung C-Y, Hurtgen BJ, Bellecourt M, Sanderson SD, Morgan EL, et al. (2012) An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine 30: 4681-4690.
13. Morgan EL, Morgan BN, Stein EA, Vitrs EL, Thoman ML, et al. (2009) Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design. Vaccine 28: 463-469.
14. Phillips JA, Morgan EL, Dong Y, Cole GT, McMahan C, et al. (2009) Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone. Bioconjug Chem 20: 1950-1957.
15. Fierer J, Waters C, Walls L, (2006) Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. J Infect Dis 193: 1323-1331.
16. Nanjappa SG, Heninger E, Wüthrich M, Gasper DJ, Klein BS, (2012) Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog 8: e1002771 doi:10.1371/journal.ppat.1002771.
17. Hurtgen BJ, Hung C-Y, Ostroff GR, Levitz SM, Cole GT, (2012) Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis. Infect Immun 80: 3960-3974.
18. Rosa DS, Ribeiro SP, Cunha-Neto E, (2010) CD4+ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp (Warsz) 58: 121-130.
19. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM, (2010) Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded β-glucan particles. MBio 1: e00164-10.
20. Ikeuchi N, Futami J, Hosoi A, Noji S, Kurachi M, et al. (2010) Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide. Biochem Biophys Res Commun 392: 217-222.
21. Tesz GJ, Aouadi M, Prot M, Nicoloro SM, Boutet E, et al. (2011) Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J 436: 351-362.
22. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, et al. (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine in infants previously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial. Lancet 381: 1021-1028.
23. Rappuoli R, Mandl CW, Black S, De Gregorio E, (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11: 865-872.
24. Morgan EL, Thoman ML, Sanderson SD, Phillips JA, (2010) A novel adjuvant for vaccine development in the aged. Vaccine 28: 8275-8279.
25. Livingston B, Crimi C, Newman M, Higashimoto Y, Appella E, et al. (2002) A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 168: 5499-5506.
26. Yano A, Onozuka A, Asahi-Ozaki Y, Imai S, Hanada N, et al. (2005) An ingenious design for peptide vaccines. Vaccine 23: 2322-2326.